Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study
| Project/Area Number |
15K19750
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | アルツハイマー型認知症 / リチウム / ランダム化比較試験 / Alzheimer's disease / Alzheimer disease / Lithium / アルツハイマー病 |
|---|
| Outline of Final Research Achievements |
Previous studies suggest that lithium inhibits the progression of cognitive dysfunction of Alzheimer disease. In 2015, we conducted a systematic review and a meta-analysis of randomized controlled trials and reported that lithium may have the effect of inhibiting the progress of cognitive dysfunction on Alzheimer disease. Based on these results, we started a double-blind, placebo-controlled, randomized controlled trial on the efficacy and safety of lithium on Alzheimer disease for Japanese population. Currently, this trial is recruiting subjects.
|
Report
(4 results)
Research Products
(2 results)
